“As more CRO’s and those responsible for today’s clinical trials grapple with sudden changes in the landscape – from budget-consuming delays to challenging patient enrollment – the possibility of moving clinical trials, during any phase, to Latin America generated conversation and questions during my presentation at DIA on June 22nd” said Sara Tylosky, CEO Farmacon Global. “Since this timely topic received so much interest, I am linking the presentation so you will take a minute to open and review it and see if it speaks to any of your concerns.
“Individuals responsible for trials based in the United States, Europe, and especially now, coming out of Ukraine, are challenging themselves to find new solutions in this changed world – from decentralized trial technologies to ‘hands-on’ regulatory and patient relationships. The presentation linked above presents two case studies that clearly outline proven results for clinical trials in Latin America, from niche-market rare disease to vast vaccination study requirements, as conducted by Farmacon Global a Strategic CRO of Medical Specialists.”
“In June, while attending the BIO 2022 and DIA 2022 conferences, it was clear to me that TRUST is still a key factor when running any portion of a clinical trial. Sponsors can trust conducting trials in Latin America now with our connectivity and expertise,” said Tylosky. “In our value-system TRUST means: (T) total (R) real (U) understanding (S) Syncs w / (T) time.”
Farmacon Global is a strategic CEO of medical consultants, providing solutions to accelerate clinical trials in emerging markets – with a specialty in Latin America and emerging markets with in-place medical associates and KOL alliances. Specialties include rare disease, cancer, immunology and infectious disease.
